November 2009

Fri, 08/28/2009 - 03:27 By Sabine Vollmer

RTP Wrapup 8/28

Duke University Health System announced plans for a $700 million cancer center, GlaxoSmithKline's diet pill Alli is being investigated for possibly causing serious liver damage and Wall Street observers project a flurry of companies may try to go public after Labor Day.

Read more...
Tags: Tranzyme, GSK, Duke, solar 0 Comments
Fri, 08/21/2009 - 04:53 By Sabine Vollmer

RTP Wrapup 8/21

Bayer CropScience wants to buy a neighbor in Research Triangle Park to boost its research and development of genetically modified crop seeds, a Canadian study gets GlaxoSmithKline's diabetes drug Avandia back into the news and the Triangle gets a nod for its nanotech research.

Read more...
Tags: rtp, nanotech, Bayer CropScience, Avandia 0 Comments
Thu, 08/20/2009 - 00:28 By Sabine Vollmer

Buying a better seed

Bayer CropScience is jockeying for a better spot in the lucrative U.S. seed market.

The German company, which employs about 400 at its U.S. headquarters in Research Triangle Park, announced Wednesday that it wants to buy Athenix, a venture-backed neighbor with 65 employees. Financial details of the deal were not announced.

Read more...
Tags: GM seeds, rtp, Monsanto, Bayer 0 Comments
Fri, 08/14/2009 - 04:35 By Sabine Vollmer

RTP Wrapup 8/13

RTI International and two Durham drug development companies hauled a lot of cash into the Triangle, a national research team led by the University of North Carolina will look for new cancer-fighting medicines and grassroots support for entrepreneurs is alive and well in the Triangle.

Read more...
Tags: UNC, RTI, fundraising, CED 0 Comments
Thu, 08/13/2009 - 16:21 By Sabine Vollmer

Grassroots business support and a free meal

North Carolina's Research Triangle area is known as a research and development hub where several large companies have operations, including IBM, GlaxoSmithKline, Biogen Idec and Quintiles Transnational. But the area's true strength lies in its many small companies, startups and mid-size businesses, where discoveries are turned into tomorrow's products.

Read more...
Tags: rtp, entrepreneurship, CED 0 Comments
Tue, 08/11/2009 - 16:23 By Sabine Vollmer

Biotech industry takes two on the chin

The biotech industry, one of North Carolina's premier engines for job creation, will have to do with less support from the state over the next two years.

On Tuesday, legislators finished a grueling session that had been dominated by spending cuts to close a multi-billion dollar shortfall in revenue. The cuts will reduce the amount of funding the N.C. Biotechnology Center will receive during the current fiscal year to $14.8 million, from $17.5 million in fiscal 2009.

Read more...
Tags: rtp, jobs, incentives, biotech 0 Comments
Thu, 08/06/2009 - 19:44 By Sabine Vollmer

RTP Wrapup 8/9

This week, the Triangle scored a major research accomplishment, watched a homegrown company test Wall Street and learned that Raleigh is better than Silicon Valley for reasons that have nothing to do with state government or the Cameron Village sewer worms.

UNC-led research team deconstructs HIV genome

Bad news for the human immunodeficiency virus, the fickle virus that continues to spread AIDS despite more than 20 years of research to stop it. Good news for patients - potentially.

Read more...
Tags: social media, rtp, Inspire, HIV 0 Comments
Tue, 08/04/2009 - 13:45 By Sabine Vollmer

Icagen doing better

After months of wrangling with an influential investor - the argument included calls for the resignation of the chief executive - things are looking up again at Icagen, a Durham company working on painkillers and asthma and epilepsy treatments.

At least for the moment they are.

Icagen's stock rallied Monday after the Food and Drug Administration gave Icagen the green light to start testing its epilespy drug in photosensistive patients. Until then, the FDA had had a partial clinical hold on the drug.

Read more...
Tags: rtp, Icagen, pharma, epilepsy 0 Comments

Subscribe to our Blog Feed

Categories

Tags

Archives